Chimerix Plans Q3 2024 Financial Results Conference Call
Chimerix to Host Q3 2024 Financial Results Call
Chimerix, a pioneering biopharmaceutical company dedicated to improving patient outcomes for those struggling with severe illnesses, is gearing up to share its latest financial results. The call will take place on November 7, 2024, at 8:30 a.m. ET. Investors and stakeholders are encouraged to join this important discussion via a live conference call.
Live Conference Call Details
To partake in this significant event, please dial (646) 307-1963 for domestic calls or (800) 715-9871 for international participants. It is advisable to connect at least five minutes earlier for a seamless experience. Participants should mention conference ID 6580777 when joining the call.
Audio Webcast Availability
In addition to the phone conference, Chimerix will also provide a live audio webcast through its Investor Relations website. Those who cannot attend the live session will have the opportunity to access an archived version of the webcast roughly two hours following the conclusion of the call. This offers a convenient way for interested parties to stay informed.
About Chimerix
Founded on a commitment to address serious health challenges, Chimerix specializes in developing pharmaceuticals that positively affect the lives of patients battling destructive diseases. One of its leading candidates is dordaviprone (ONC201), presently undergoing clinical trials for H3 K27M-mutant diffuse glioma, representing the company's advancement in fighting this aggressive form of cancer.
Ongoing Research and Development
Chimerix is also evaluating ONC206 through Phase 1 dose escalation studies. These studies aim to gather crucial safety and pharmacokinetic data, reinforcing the company’s commitment to pushing the boundaries of medical science for the benefit of patients.
Contact Information
For further inquiries, interested parties can reach out to Will O'Connor at Stern Investor Relations by calling 212-362-1200. You may also contact him via email at will@sternir.com. Chimerix values communication with its stakeholders and aims to provide comprehensive updates on its progress.
Frequently Asked Questions
What is the purpose of the Chimerix conference call?
The conference call aims to report financial results for Q3 2024 and discuss the company's operational updates.
How can I listen to the live conference call?
You can listen by dialing the provided numbers or through the live audio webcast on Chimerix's website.
What is dordaviprone and its significance?
Dordaviprone (ONC201) is a leading candidate in clinical trials aimed at treating H3 K27M-mutant diffuse glioma, showcasing Chimerix's innovative approaches in oncology.
Will there be an archived version of the call?
Yes, Chimerix will provide access to an archived version of the webcast approximately two hours after the live event.
Who can I contact for investor relations?
Will O'Connor at Stern Investor Relations can be contacted at 212-362-1200 or via email at will@sternir.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
